TAC Regimen Dosage for Invasive Breast Cancer
The standard TAC regimen consists of docetaxel 75 mg/m² IV, doxorubicin 50 mg/m² IV, and cyclophosphamide 500 mg/m² IV, all administered on day 1 and cycled every 21 days for 6 cycles, with mandatory filgrastim (G-CSF) support for all cycles. 1
Detailed Dosing Specifications
Component Doses
- Docetaxel: 75 mg/m² IV infused over 1 hour on day 1
- Doxorubicin (Adriamycin): 50 mg/m² IV on day 1
- Cyclophosphamide: 500 mg/m² IV on day 1
Administration Schedule
- Cycle frequency: Every 21 days
- Total number of cycles: 6 cycles
- Critical requirement: All cycles must be administered with filgrastim (G-CSF) support 1, 2
FDA-Approved Dosing Context
The FDA label for docetaxel specifically endorses this regimen for adjuvant treatment of operable node-positive breast cancer, stating: "the recommended Docetaxel Injection dose is 75 mg/m² administered 1 hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks for 6 courses. Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities." 2
Evidence Supporting This Regimen
TAC is listed as a "Preferred Adjuvant Regimen" by NCCN guidelines and has demonstrated superiority over FAC (fluorouracil-doxorubicin-cyclophosphamide) in clinical trials. 1, 3 The 2018 ASCO guidelines specifically note that "Docetaxel-doxorubicin-cyclophosphamide × 6 (superior to fluorouracil-doxorubicin-cyclophosphamide × 6)" is a recommended regimen for early breast cancer. 3
Critical Safety Considerations
Mandatory G-CSF Support
The guidelines explicitly state that all cycles are administered with filgrastim support 1. This is non-negotiable given the high rate of grade 4 neutropenia (68-70% of cycles) and febrile neutropenia (5.5-6% of cycles) observed in clinical trials. 4, 5
Cardiac Monitoring
- Doxorubicin cumulative dose in TAC regimen: 300 mg/m² (6 cycles × 50 mg/m²)
- This is below the 550 mg/m² threshold associated with significantly increased cardiomyopathy risk 6
- Baseline LVEF assessment required before treatment
- Cardiac monitoring should occur at baseline, 3,6, and 9 months 1
Common Pitfalls to Avoid
- Do not omit G-CSF prophylaxis: Primary prophylaxis is required, not secondary prophylaxis after neutropenic events occur
- Do not reduce doses preemptively: The regimen's efficacy depends on maintaining dose intensity (relative dose intensity >98% in pivotal trials) 5
- Do not substitute doxorubicin doses: The 50 mg/m² doxorubicin dose in TAC is specifically validated; do not use the higher 60 mg/m² dose from AC regimens
- Sequence matters: Docetaxel is administered 1 hour after doxorubicin and cyclophosphamide 2
Dose Modifications
Hepatic Impairment
For elevated bilirubin:
- Bilirubin 1.2-3 mg/dL: Reduce docetaxel by 50%
- Bilirubin 3.1-5 mg/dL: Reduce docetaxel by 75%
- Bilirubin >5 mg/dL: Contraindicated 2, 6
Hematologic Toxicity
Despite high rates of neutropenia, dose reductions are generally not recommended if G-CSF support is adequate. Consider dose delays for prolonged myelosuppression rather than dose reductions to maintain efficacy.
Alternative Considerations
While TAC remains a preferred regimen, the 2025 NCCN guidelines note that for patients at higher cardiac risk or those seeking to avoid anthracyclines, TC (docetaxel 75 mg/m² + cyclophosphamide 600 mg/m² every 21 days for 4 cycles) is an acceptable alternative, though it contains no anthracycline. 7